Search
Noeletta McKenzie is a Champion for Change, RHDAustralia, and community representative and advocate for the START study.
Liana’s story begins nine years ago.
News & Events
Old, painful rheumatic heart disease treatment could be phased outAn international trial reveals 95% of rheumatic heart disease patients prefer less painful penicillin injections under the skin, aiming to improve treatment adherence.
News & Events
Unified response critical to address spread of ‘flesh eating’ bacteriaA surge in invasive group A streptococcal reports in Australia has prompted The Kids Research Institute Australia researchers to call for a unified national public health response, with cases tipped to increase.
News & Events
Study suggests flu vaccine may take edge off RSV casesA The Kids Research Institute Australia study has suggested the seasonal flu vaccine for children could also protect them from respiratory syncytial virus (RSV), with the dual benefit easing pressure on hospitals.
News & Events
The Kids researchers lead national trial to fight sepsis in premature infantsThe Kids Research Institute Australia researchers will lead a new national clinical trial (COSI-2) to determine whether topical coconut oil can reduce late onset sepsis in extremely preterm infants.
Contact us If you'd like to get in touch, please contact Marie Nadal-Sims by phone or email. Phone: (08) 6319 1001 Email: IICPerth@thekids.org.au All
A decade long partnership with Wesfarmers Ltd. and the Wesfarmers Centre of Vaccines and Infectious Diseases has led to world-class paediatric research and important collaborations fuelling the Centre’s trajectory towards easing the burden of infectious diseases.
News & Events
The Kids Research Institute Australia researcher wins Eureka Prize for Emerging Leader in SciencePaediatric infectious disease expert and clinician-scientist Associate Professor Asha Bowen has been named as the Emerging Leader in Science at the country’s most prestigious science awards – the Australian Museum Eureka Prizes.
Research
Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1–9 years: two phase 2 randomised, controlled, observer-blinded studiesThe meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) is licensed for use in children aged 10 years or older for protection against invasive serogroup B meningococcal disease. Because young children are at increased risk of invasive meningococcal disease, MenB-FHbp clinical data in this population are needed.